Copyright investors
On Wednesday, Edwards Lifesciences (EW) received a positive adjustment to its Relative Strength (RS) Rating, from 68 to 75. IBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database. History reveals that the market's biggest winners tend to have an RS Rating of above 80 as they launch their largest runs. See if Edwards Lifesciences can continue to show renewed price strength and clear that threshold. Edwards Lifesciences is in a buy zone after climbing above an 83.00 buy point in a flat base. The proper buying range is up to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity.. Earnings-per-share growth decreased in the company's latest report from 8% to 0%, but the top line rose from 12% to 15%. Edwards Lifesciences earns the No. 8 rank among its peers in the Medical-Products industry group. Axogen (AXGN), TransMedics Group (TMDX) and Insulet (PODD) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
